Bayer Expands Finerenone Development Programme With Three Phase III Studies

Bayer HealthCare announced the expansion of the clinical development programme for its oral, non-steroidal mineralocorticoid receptor antagonist finerenone (BAY 94-8862) with three Phase III studies. The studies will investigate the efficacy and safety of finerenone in patients with chronic heart failure and patients with diabetic kidney disease with the first patients expected to be enrolled by the year-end.

The company's decision was based on data of four dose-finding studies in patients with chronic heart failure and diabetic kidney disease.

Joerg Moeller, Member of the Bayer HealthCare Executive Committee and Head of Global Development, said: "We are excited about finerenone being the first mineralocorticoid receptor antagonist that is being developed in parallel in chronic heart failure and diabetic kidney disease. The studies will investigate whether finerenone can reduce cardiovascular morbidity and mortality as well as the progression of renal disease in these patients with a well-tolerated safety profile."

This article was originally published on RTT News.